Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice

Blood

Volumn 98, Issue 5, 2001, Pages 1607-1613

  Cetkovic Cvrlje, Marina ^a,b   Roers, Bertram A ^a,b   Waurzyniak, Barbara ^a,b   Liu, Xing Ping ^a,b   Uckun, Fatih M ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ENZYME INHIBITOR; JANUS KINASE; JANUS KINASE 3; METHOTREXATE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IRRADIATION; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; RECIPIENT; SPLEEN CELL; SURVIVAL;

EID: 0035469862     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1607     Document Type: Article

References (37)

1. O'Reilly RJ, Papadopoulos EB. Allogeneic Transplantation. Baltimore, MD: William & Wilkins; 1997.
2. Henslee-Downey PJ. Mismatched bone marrow transplantation. Curr Opin Oncol. 1995;7:115-121.
3. Leelasiri A, Greer JP, Stein RS, et al. Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant. 1995;15:401-405.
4. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood. 1983;62:941-964.
5. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T-cell depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988;3:445-456.
6. Marmont AM, Horowitz M, Gale R, et al. T cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
7. Poynton C. T cell depletion in bone marrow transplantation. Bone Marrow Transplant. 1988;3:265-279.
8. + hematopoietic progenitor cells. Cancer Invest. 1996;14:589-596.
9. Apperly JF, Jones L, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant. 1986;1:53-60.
10. Miyazaki T, Taniguchi T. Coupling of the IL2 receptor complex with non-receptor protein tyrosine kinases. Cancer Surv. 1996;27:25-39.
11. Levy DE. The house that Jak/Stat built. Cytokine Growth Factor Rev. 1997;8:81-90.
12. Ihle JN, Kerr IR. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69-74.
13. Darnell JEJ, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
14. Nosaka T, Van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800-802.
15. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 1995;270:794-797.
16. Villa A, Sironi M, Macchi P, et al. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene, Blood. 1996;88:817-823.
17. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic phenotypic and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387.
18. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977-984.
19. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
20. Sudbeck EA, Liu X-P, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin Cancer Res. 1999;5:1569-1582.
21. Uckun FM, Ek O, Liu X-P, Chen C-L. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]. Clin Cancer Res. 1999;5:2954-2962.
22. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliott JF, Leiter EH. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta cell antigens. Diabetes. 1997;46:1975-1982.
23. Hanson MS, Cetkovic-Cvrlje M, Ramiya VK, et al. Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. J Immunol. 1996;157:1279-1287.
24. Uckun FM, Ledbetter JA. Immunobiologic differences between normal and leukemic human Bcell precursors. Proc Natl Acad Sci U S A. 1988;85:8603-8607.
25. Uckun FM, Myers DE, Jaszcz W, Haissig S, GajlPeczalska K, Ledbetter JA. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of antiCD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood. 1990;76:2449-2456.
26. Bryson JS, Jennings CD, Caywood BE, Dix AR, Lowery DM, Kaplan AM. Enhanced graft-versushost disease in older recipient mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:721-728.
27. Wingard JR, Piantadosi S, Santos GW, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol. 1990;8:820-830.
28. Thomas ED, Clift RA. Indications for marrow transplantation in chronic myelogenous leukemia. Blood. 1989;73:861-864.
29. Barrett AJ, Horowitz MM, Gape RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 1989;74:862-871.
30. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-1871.
31. Dinsmore R, Kirkpatrick D, Flomenberg N, et al. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood. 1983;62:381-388.
32. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLAidentical sibling donor: a prospective randomized study. Blood. 2000;96:2391-2398.
33. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of graft-versus-host disease in patients undergoing marrow transplants? Blood. 1990;76:1037-1045.
34. Atkinson K, Biggs J, Concannon A, et al. A prospective randomized trial of cyclosporine and methotrexate versus cyclosporine, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for hematological malignancy. Aust N Z J Med. 1991;21:850-856.
35. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine and cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective randomized trial. Blood. 1997;89:3880-3887.
36. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 1996;21:359-366.
37. Grossman WJ, Verbsky JW, Yang L, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood. 1999;94:932-939.